Post by
crow27 on Nov 30, 2020 12:35pm
RS
If you have the goods a RS will not hurt you. It actually helps in that your share count drops dramatically. Now if you have nothing going for you and you are just trying to reduce your float then your stock will continue to slide after the split.
ATE is not in that situation as the good news is about to be announced and that will drive the stock higher. Remember a .10 cent gain or drop after the split is like us gaining or losing .01 cent before the split.
Nothing to fear about the RS, they are doing it from a situation of strength not weekness.
Comment by
Tricks on Nov 30, 2020 4:32pm
Unfortunately people on this board think because the science is good that it'll translate to the stock price rising which hasn't been the case. What has ATE done since the phase 2 results? Sell shares, dilute shares and now a reverse split all the while stock has taken at tumble from .89 so I'm not sure why people are looking at this RS with such optimism and confidence.
Comment by
endpntplay on Nov 30, 2020 5:09pm
Did any of those companies have a lead drug or technology that failed a clinical trial? By my count antibe hasn't failed one yet. Market confusion around safety killed them 4 years ago though. Hence, the dilution to stay afloat. Antibe is the real deal now.
Comment by
Pandora on Nov 30, 2020 10:03pm
Actually Briacell (BCT) is in a partnership program with both Merck and Incyte using their drugs Keytruda & INCMGA00012. They are supposed to make a presentation on progress Dec. 9 - 11. They also recently announced a collaboration with the National Cancer Institute recently. So they have been in the limelight but to no avail so far.
Comment by
endpntplay on Nov 30, 2020 11:45pm
Yeah took a look at their website not very impressive, and Merck hands out keytruda like candy for small bios to develop in combination.